RxDoctor Payments Data

Elsie Haynes, DO

Family Medicine · Pueblo, CONPI 1538519384

Payments from drug & device makers

$582in general payments, 2019–2025

Across 30 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$168
  • AbbVie$81
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$75
  • Idorsia Pharmaceuticals US Inc$52
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$36
  • Innocoll Pharmaceuticals Limited$26
  • plus $145 from 8 others

What the payments were for

  • Food & beverage$582100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$582 in reported general payments places this provider in the 75th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$17,986
Medicare patients
38
Services billed
200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$24,632
EliquisApixaban18$23,723
Spiriva RespimatTiotropium Bromide13$6,763
AbrysvoRsv Vacc, Pref A And Pref B/Pf21$6,561
Gabapentin83$1,273
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,043
Omeprazole63$883
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$821
Duloxetine Hcl25$603
Easy Touch Pen NeedlePen Needle, Diabetic11$586
Esomeprazole Magnesium16$579
Ketoconazole13$545
Diclofenac Sodium21$538
Atorvastatin Calcium67$529
Albuterol Sulfate HfaAlbuterol Sulfate12$481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$168$24,63225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →